Ganglioneuroblastoma, Nodular
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Ganglioneuroblastoma, Nodular is an emerging landscape with 13 programs across 8 companies. The most active players are Avyxa, Pfizer, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Avyxa
2 programs
Pfizer
2 programs
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
United Therapeutics
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Alnylam Pharmaceuticals
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
92%
Small molecule
12 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
1
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)